Samsung C&T (028260) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
23 Jun, 2026Executive summary
3Q24 sales reached KRW 10,310bn, down KRW 695bn year-over-year, with operating profit at KRW 736bn, a decrease of KRW 164bn from 3Q23.
Net profit for 3Q24 was KRW 560bn, down KRW 174bn year-over-year, with controlling interest at KRW 448bn.
Revenue for the nine months ended September 30, 2024, was ₩32.1 trillion, with operating profit at ₩2.35 trillion and net income attributable to controlling interests at ₩1.75 trillion.
The company operates across construction, trading, fashion, resort, food distribution, and bio segments.
Financial highlights
Year-to-date (1-3Q) sales increased by KRW 315bn to KRW 32,111bn compared to the same period last year.
Gross profit for 3Q24 was KRW 1,711bn, a decrease of KRW 202bn compared to 3Q23.
Total assets at September 30, 2024, were ₩62.4 trillion; total liabilities were ₩23.9 trillion; equity was ₩38.4 trillion.
Cash and cash equivalents at period-end were ₩3.46 trillion.
Operating cash flow for the period was ₩1.87 trillion.
Outlook and guidance
Continued focus on hydrogen and data center projects, with new contracts and equity investments secured for future growth.
Expansion into green hydrogen and data center markets, targeting long-term partnerships and early project involvement.
Domestic construction market expected to remain flat in 2024, with slight growth in 2025 as interest rates ease.
Global construction market projected to grow at a 7.1% CAGR through 2027, but faces geopolitical and supply chain risks.
The company maintains a stable dividend policy and continues to focus on cash flow and capital efficiency.
Latest events from Samsung C&T
- H1 2024 net profit reached ₩1.3 trillion on ₩21.8 trillion revenue, led by bio and construction.028260
Q2 202423 Jun 2026 - Net profit rose 14% year-over-year as Bio and T&I growth offset declines in other segments.028260
Q1 202523 Jun 2026 - H1 2025 revenue KRW 19.76T, net income KRW 1.09T, strong bio/construction, Bio outlook raised.028260
Q2 202523 Jun 2026 - Nine-month revenue hit KRW 29.91 trillion, led by bio growth and strong liquidity.028260
Q3 202523 Jun 2026 - Q1 2026 profit and revenue rose, driven by trading and bio, with strong cash flow and liquidity.028260
Q1 202622 Jun 2026 - Net profit rose 15% year-over-year in 4Q 2024, driven by Bio and T&I growth.028260
Q4 202410 Mar 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026